High-Dose Vitamin C to Treat Cancer

Evidence Review created on 10/31/2026 using AI4L + evidence-mcp / Opus 5.5

Also known as: Intravenous Vitamin C, IVC, High-Dose Intravenous Vitamin C, HDIVC, Pharmacological Ascorbate, Pharmacologic Ascorbate, High-Dose Ascorbate, Intravenous Ascorbic Acid, Ascorbic Acid, Ascorbate, Sodium Ascorbate, Vitamin C Megadosage, ASCOR, Pascorbin

Motivation

High-dose vitamin C means infusing grams of vitamin C (ascorbic acid) directly into a vein, usually two or three times a week. Infusion bypasses the gut and raises blood levels far above anything food or oral supplements can reach. At these levels vitamin C is thought to act less as an antioxidant and more as a source of hydrogen peroxide, a reactive molecule that some cancer cells handle poorly.

The idea dates to the 1970s, when a Nobel Prize-winning chemist and a Scottish surgeon proposed vitamin C as a cancer treatment, and it has since moved between dismissal and renewed interest. Infusions are widely offered by complementary-medicine clinics, and university groups in the United States, China and Europe have tested them alongside chemotherapy and radiation for pancreatic, lung and brain cancers, among others.

This review examines what controlled human studies show about survival, side effects of cancer treatment and quality of life, which harms and drug interactions have been documented, how infusion regimens differ, and how proactive patients willing to commit to frequent infusions can weigh the evidence.

Benefits - Risks - Protocol - Conclusion

The items below give high-level overviews of intravenous vitamin C in cancer care, from podcast discussion to government and academic summaries.

  • Vitamin C: Oral vs. Intravenous, Immune Effects, Cancer, Exercise Adaptation & More - Rhonda Patrick

    Solo episode explaining why intravenous dosing reaches blood concentrations oral intake cannot, the pro-oxidant hypothesis of cancer cell killing, Linus Pauling’s early cancer work and safety considerations such as kidney stones.

  • Another look at high dose vitamin C cancer therapy - Life Extension

    Summarizes three government-reviewed case reports of unexpectedly long survival after infusions and the argument that the negative Mayo Clinic trials tested only oral dosing; Life Extension sells vitamin C supplements.

  • Intravenous Vitamin C (PDQ®)–Health Professional Version - National Cancer Institute PDQ Integrative, Alternative, and Complementary Therapies Editorial Board

    Government summary of history, laboratory, animal and human studies, adverse effects and interactions; notes that the U.S. Food and Drug Administration (FDA) has not approved high-dose vitamin C for cancer.

  • Targeting cancer vulnerabilities with high-dose vitamin C - Ngo et al., 2019

    Opinion article from the Cantley and Yun laboratories on three tumor weaknesses vitamin C may exploit (redox imbalance, epigenetic reprogramming, oxygen sensing) and on biomarkers for selecting patients.

No directly relevant content was found from Andrew Huberman, Chris Kresser or Lifespan.io: their sites and web searches returned no material on high-dose intravenous vitamin C for cancer. Peter Attia’s only relevant content is a brief members-only podcast segment whose public show notes give a two-line preview, so it is not listed; no other item met the selection criteria, so four items are listed.

Grokipedia

  • Vitamin C megadosage

    Covers doses above 1 g daily, oral and intravenous, including Pauling’s cancer claims, the Mayo Clinic oral trials and the bioavailability argument for infusion; written and fact-checked by an artificial intelligence system.

Examine

  • Vitamin C

    General vitamin C page with dosing, safety and graded evidence for 36 conditions; cancer treatment is not among the graded conditions, and the intravenous doses it reviews reach 24 g.

ConsumerLab

  • Vitamin C Supplements Review

    ConsumerLab’s dedicated vitamin C page: quality testing of oral supplements, dosing and forms, plus a 2026 update on vitamin C and blood cancer; the full review requires membership.

Systematic Reviews

The following systematic reviews and meta-analyses assess the effects and harms of high-dose vitamin C in people with cancer.

Mechanism of Action

Oral vitamin C is tightly regulated: gut absorption and kidney excretion cap blood levels near 220 µM (micromolar), whereas intravenous (IV) infusion of 50 g is predicted to reach about 13,400 µM (13 mM, millimolar) (Padayatty 2004).

  • Pro-oxidant action: At millimolar levels, ascorbate generates hydrogen peroxide that killed several cancer cell lines but not normal cells (Chen 2005) and, in mice, formed selectively in tumor fluid and slowed tumor growth (Chen 2008). Tumors with more loose iron and weaker peroxide defenses are more vulnerable (Schoenfeld 2017).
  • Oncogene-specific stress: In cells and mice, tumors with mutated KRAS or BRAF (RAS-pathway growth genes common in colorectal cancer) take up oxidized vitamin C through GLUT1 (a glucose transporter), depleting glutathione and blocking GAPDH (an enzyme of sugar breakdown) (Yun 2015).
  • Epigenetic and immune effects: Vitamin C is a cofactor for TET2 (an enzyme that removes DNA methylation marks) and restored its function in leukemia models (Cimmino 2017); it also enhanced T-cell attack in mice (Magrì 2020).
  • Competing view: Vitamin C pretreatment protected blood-cancer cells from several chemotherapy drugs in cells and mice by preserving mitochondria, not through antioxidant action (Heaney 2008).
  • Pharmacology: Half-life (time for blood levels to halve) is near 2 hours (Stephenson 2013). Ascorbate distributes through SVCT transporters (sodium-dependent vitamin C transporters), is not selective for tumors, undergoes no CYP (cytochrome P450 liver enzyme) metabolism, and is excreted largely unchanged; under 0.5% of a large dose appears as oxalate (Robitaille 2009).

Historical Context & Evolution

Vitamin C entered medicine as the cure for scurvy (the bleeding and connective-tissue disease of vitamin C deficiency), and injectable ascorbic acid is still FDA-approved only for short-term scurvy treatment (ASCOR label).

Its use against cancer began with Scottish surgeon Ewan Cameron and Nobel laureate Linus Pauling, who reported that 100 terminal cancer patients given supplemental ascorbate survived more than 4.2 times longer on average than 1,000 comparison patients treated identically but without ascorbate (Cameron 1976). The comparison group was not randomized, and two Mayo Clinic randomized, double-blind trials of 10 g daily oral vitamin C then found no difference in symptoms or survival (Creagan 1979, Moertel 1985). Mainstream oncology largely set the idea aside, while integrative clinics kept offering infusions.

The picture changed when National Institutes of Health researchers in Mark Levine’s group showed that oral dosing cannot reach the concentrations produced by infusion, so the Mayo trials had tested a different exposure (Padayatty 2004). Pathology-verified case reports of long survival after infusions (Padayatty 2006) and laboratory evidence of peroxide-mediated killing led to phase 1 safety trials (Hoffer 2008) and, in the 2020s, randomized trials with mixed results. The Mayo findings remain informative for oral dosing; the open question is whether infusion, which they did not test, changes cancer outcomes.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: survival data come from single randomized trials per cancer type and a meta-analysis mixing cohort studies, and the largest randomized trial was negative.

Medium 🟩 🟩

Longer Survival When Added to Standard Treatment ⚠️ Conflicted

A meta-analysis of 8 controlled studies (2,722 adults, randomized and cohort) linked infusions with longer median survival (Qu 2025). A randomized pancreatic trial found longer survival (Bodeker 2024), and a single-arm glioblastoma (aggressive brain tumor) trial beat historical controls (past patients on standard treatment) (Petronek 2024). The largest randomized trial, 442 colorectal patients, found no overall benefit beyond a RAS-mutant subgroup (Wang 2022); a placebo-controlled prostate trial stopped for futility (judged unable to succeed) (Paller 2024). Net: a survival gain is possible in selected tumors but unproven across cancers.

Magnitude: Pooled median survival ratio (treated median survival divided by control median survival) 1.83, 95% confidence interval (CI, the range likely to contain the true effect) 1.40–2.40, vs no vitamin C (Qu 2025); pancreatic trial 16.0 vs 8.3 months, hazard ratio (HR, relative rate of death at any time) 0.46, 90% CI 0.23–0.92 (Bodeker 2024); colorectal trial 20.7 vs 19.7 months, not significant (Wang 2022).

Low 🟩

Correction of Vitamin C Deficiency ⭕️ Not Central to Treat Cancer

Infusions restore vitamin C, and injectable ascorbic acid is FDA-approved for scurvy (ASCOR label). A placebo-controlled trial in stem cell transplant recipients raised blood vitamin C at every time point (Heidari 2026). Evidence is indirect: both used doses far below cancer regimens. This bears on nutritional status, not tumor control.

Magnitude: Plasma vitamin C was significantly higher than with placebo at every measured time point; the abstract reports no outcome figure (Heidari 2026).

Tumor Response When Added to Chemotherapy ⚠️ Conflicted

Tumor shrinkage was the primary endpoint of a single-arm Iowa lung cancer trial, which beat a historical response rate (Furqan 2022). The 442-patient randomized colorectal trial found similar response rates with or without vitamin C (Wang 2022). Net: response gains are unconfirmed by randomized comparison.

Magnitude: Objective response (tumor shrinkage of at least 30%) 34.2% vs a 20% historical rate, no control group (Furqan 2022); 44.3% with vitamin C vs 42.1% with chemotherapy alone, not significant (Wang 2022).

Fewer Chemotherapy and Radiation Side Effects ⚠️ Conflicted

Antioxidant effects may ease treatment toxicity. A randomized ovarian cancer trial reported less chemotherapy toxicity (Ma 2014) and a systematic review fewer radiotherapy side effects (Shahzad 2026); a placebo-controlled prostate trial (Paller 2024) and a 442-patient colorectal trial (Wang 2022) found similar adverse-event rates. Net: no consistent reduction.

Magnitude: Severe (grade 3 or higher) treatment-related adverse events 33.5% with vitamin C vs 30.3% with chemotherapy alone (Wang 2022); the ovarian trial abstract reports reduced toxicity without a summary figure (Ma 2014).

Better Quality of Life and Less Fatigue ⚠️ Conflicted

An uncontrolled terminal-cancer study reported less fatigue, nausea and pain (Yeom 2007), and a retrospective breast cancer cohort by an employee of Pascoe, which sells infused vitamin C, reported less nausea and fatigue (Vollbracht 2011). A placebo-controlled trial found no quality-of-life difference (Paller 2024). Net: unconfirmed by controlled trials.

Magnitude: Global health score rose from 36 to 55 points on a 100-point scale after one week, no control group (Yeom 2007); no significant difference vs placebo in the controlled trial (Paller 2024).

Reduced Systemic Inflammation ⭕️ Not Central to Treat Cancer

Infusions are proposed to dampen tumor-associated inflammation. A Riordan Clinic case series (the clinic sells infusions) reported falling C-reactive protein (CRP, a blood inflammation marker) and inflammatory cytokines (immune signaling proteins) (Mikirova 2012); a systematic review concurred (Shahzad 2026). Evidence is uncontrolled. This bears on inflammatory burden, not tumor control.

Magnitude: CRP fell in 75% of 45 treated patients, no control group (Mikirova 2012).

Speculative 🟨

Stronger Response to Immunotherapy

In mice, high-dose vitamin C slowed tumors through T cells and, with checkpoint inhibitors (drugs that release immune-cell brakes), cured some tumors (Magrì 2020). Basis is animal work only.

Benefit-Modifying Factors

  • Genetic factors (tumor mutations): Tumors with RAS mutations had longer progression-free survival (time alive without cancer growth) with vitamin C in a prespecified colorectal subgroup (Wang 2022); TET2-mutant clonal cytopenia (a blood-cell precancer) showed no responses (Xie 2024).
  • Baseline biomarkers: Vitamin C deficiency, high CRP and large tumor burden lowered the blood levels reached after infusion (Mikirova 2013, Riordan Clinic, which sells infusions). Higher tumor iron content on imaging predicted longer glioblastoma control (Petronek 2024).
  • Sex: No sex-specific difference in benefit has been reported; the negative docetaxel trial enrolled only men with prostate cancer (Paller 2024), and several positive signals come from mixed-sex pancreatic and lung trials (Bodeker 2024, Furqan 2022).
  • Pre-existing conditions (cancer type and stage): Positive signals cluster in pancreatic cancer, lung cancer and glioblastoma (Bodeker 2024, Furqan 2022, Petronek 2024), with no benefit in heavily pretreated prostate cancer (Paller 2024); metastatic disease lowered achieved blood levels (Mikirova 2013).
  • Age: Trials enrolled mainly adults in their 50s to 70s; no age-specific analysis of benefit exists. Older adults may tolerate infusion volume and sodium load less well, which can limit achievable doses.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: serious harms rest on case reports and a practitioner survey, randomized cancer trials found no excess adverse events, and the critical-illness trials showing harm are indirect.

Medium 🟥 🟥

False Readings on Glucose Meters and Lab Tests

Ascorbate is a strong reducing agent that distorts oxidation-based tests, including fingerstick glucose and urine glucose, nitrite and leukocyte tests, during and up to 24 hours after infusion (ASCOR label). Blood-sample studies from the Carr group in New Zealand (Rosengrave 2022) and a Dutch laboratory group (Ten Berge 2021) found meter-specific interference. One patient treated for apparent diabetic ketoacidosis (acid buildup from insulin shortage) developed severe hypoglycemia (low blood sugar) and died (Orija 2021).

Magnitude: Meter glucose rose 1.4 mmol/L for every 1 mmol/L of added ascorbate (95% CI 1.0–1.8); this was a spiking experiment compared against laboratory glucose, no control group (Rosengrave 2022).

Low 🟥

Oxalate Kidney Injury and Kidney Stones

Part of each dose becomes oxalate, which can crystallize in kidney tubules (oxalate nephropathy). Case reports describe kidney failure after infusions for cancer (Zou 2025, Giffen 2019); a scoping review named prior kidney dysfunction a key risk factor, with many cases confounded by the underlying disease or medications (Carr 2026).

Magnitude: Not quantified in available studies. Only case reports exist for cancer-dose infusions; the one randomized comparison, in sepsis (overwhelming infection) at far lower doses, reported similar rates of severe acute kidney injury without a figure in its abstract (Lamontagne 2022).

Hemolysis in G6PD Deficiency

High-dose ascorbate generates oxidant stress that red cells lacking G6PD cannot neutralize, causing hemolysis. A systematic case review found 14 reports, 71.4% with G6PD deficiency, half with complications such as kidney injury, and one death (Juneja 2022).

Magnitude: Not quantified in available studies. Evidence consists of case reports without a comparison group, so no incidence figure exists.

Worse Outcomes in Critical Illness ⚠️ Conflicted

Placebo-controlled trials in sepsis (Lamontagne 2022) and severe burns (Stoppe 2026), sharing investigators, found more deaths or persistent organ failure with infusions. Evidence is indirect: lower doses, critically ill patients. A scoping review found no consistent excess harm (Yanase 2020). Net: harm signal confined to critical illness.

Magnitude: Death or persistent organ dysfunction at 28 days 44.5% with vitamin C vs 38.5% with placebo (risk ratio, the relative risk of the outcome, 1.21, 95% CI 1.04–1.40) (Lamontagne 2022); 28-day mortality 15.0% vs 7.6% in burns (adjusted risk ratio 1.96, 95% CI 1.32–2.90) (Stoppe 2026).

Delayed or Forgone Effective Cancer Treatment

When alternative therapies replace conventional treatment, survival falls. A matched U.S. cohort found higher mortality in patients choosing alternative medicine alone for curable cancers (Johnson 2018). Evidence is indirect: it covers alternative medicine broadly, not vitamin C infusions specifically.

Magnitude: HR 2.50 (95% CI 1.88–3.27) for death with alternative medicine alone vs conventional treatment (Johnson 2018).

Reduced Chemotherapy Effectiveness ⚠️ Conflicted

Vitamin C pretreatment blunted chemotherapy killing in cells and mice (Heaney 2008). A placebo-controlled prostate trial showed a nonsignificant trend toward shorter survival (Paller 2024), while a larger colorectal trial and a smaller pancreatic trial showed no harm (Wang 2022, Bodeker 2024). Net: no consistent harm shown.

Magnitude: Median survival 15.2 months with vitamin C vs 29.5 months with placebo (HR 1.98, 95% CI 0.85–4.58; not significant) (Paller 2024).

A practitioner survey reported mostly minor effects such as lethargy, mental-status changes and phlebitis (vein inflammation) (Padayatty 2010); a trial noted dry mouth and chills (Allen 2019). A randomized trial found no added adverse events (Bodeker 2024). Net: mild and infrequent.

Magnitude: 101 of 9,328 patients (about 1%) reported side effects, no control group (Padayatty 2010).

Speculative 🟨

Selection of More Aggressive Resistant Tumor Cells

Pancreatic cancer cells made resistant to high-dose ascorbate became more invasive and metastatic in mice (Pope 2025). Basis is cell and animal work only.

Risk-Modifying Factors

  • Genetic polymorphisms: G6PD deficiency, most often affecting males because the gene is X-linked, raises hemolysis risk (Juneja 2022); inherited oxalate-overproduction disorders (primary hyperoxaluria) would add to oxalate load, a risk inferred from mechanism.
  • Baseline biomarkers: Raised creatinine signals reduced kidney clearance, a key risk factor for oxalate injury (Carr 2026); high ferritin or iron saturation suggests iron overload, in which vitamin C’s iron-mobilizing chemistry is a theoretical concern.
  • Sex: Men made up 78.6% of published hemolysis cases (Juneja 2022), consistent with X-linked G6PD deficiency; no other sex differences in harm are documented.
  • Pre-existing conditions: Kidney impairment and prior oxalate stones raise nephropathy risk (ASCOR label); diabetes adds glucose-meter risk; heart failure adds fluid and sodium-load concerns, inferred from infusion volume.
  • Age: The label lists geriatric patients among those at increased risk of oxalate nephropathy (ASCOR label); age-related decline in kidney function and dehydration magnify this.

Key Interactions & Contraindications

Documented interactions:

  • Point-of-care glucose meters and urine dipsticks: Inaccurate (false-negative) glucose, nitrite, bilirubin and leukocyte results during and up to 24 hours after infusion (ASCOR label); falsely high meter glucose probably led to fatal insulin-induced hypoglycemia (Orija 2021). Laboratory venous glucose avoids the interference.
  • Antibiotics (erythromycin, doxycycline, streptomycin, kanamycin, lincomycin) and bleomycin: Possible reduced antibiotic activity; bleomycin is inactivated by ascorbic acid in vitro (ASCOR label). The label calls for stopping ascorbic acid if antibiotic efficacy appears reduced.
  • Amphetamine and urine-pH-sensitive drugs (fluphenazine): Urine acidification can lower blood levels and blunt effect (ASCOR label). The label calls for standard monitoring of therapy.
  • Warfarin: No anticoagulation change at 1 g daily for 2 weeks; limited case reports suggest interference (ASCOR label); no interaction in a human study (Weintraub 1974), but warfarin resistance in a breast cancer case (Gao 2024). INR (international normalized ratio, a clotting test) monitoring continues.
  • Antiretrovirals (drugs suppressing human immunodeficiency virus, HIV; e.g., indinavir): Vitamin C 1 g daily lowered indinavir peak level by 20% and total exposure by 14% in healthy volunteers (Slain 2005); low levels risk loss of HIV control. Viral load monitoring is common practice.
  • Deferoxamine (an iron-removing drug): The label reports impaired heart function when vitamin C is combined with it in iron overload, limits vitamin C to 200 mg daily in adults and advises against combining in heart failure (Desferal label).
  • Iron supplements and intravenous iron: Vitamin C enhances absorption of nonheme (plant-type) iron in humans, strongly with single meals and less across a whole diet (Cook 2001); added iron-driven oxidant reactions could worsen iron overload. A ferritin check before combining identifies overload.
  • High-dose oral vitamin C supplements: Oral ascorbic acid 2 g daily raised urinary oxalate 20–33% versus placebo (Traxer 2003), adding to the oxalate load of infusions. Common practice avoids large oral doses on infusion days.
  • Acetaminophen (paracetamol): Oral ascorbic acid 3 g reduced acetaminophen sulfate conjugation and lengthened its half-life from 2.3 to 3.1 hours in volunteers (Houston 1976), raising acetaminophen exposure. Common practice keeps acetaminophen within label limits on infusion days.
  • Chemotherapy and radiation regimens: No added toxicity found with gemcitabine plus erlotinib (Monti 2012), carboplatin–paclitaxel (Ma 2014), FOLFOX (fluorouracil, leucovorin, oxaliplatin) (Wang 2022), gemcitabine–nab-paclitaxel (Bodeker 2024), temozolomide–radiation (Allen 2019) or docetaxel (Paller 2024).

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Bortezomib and ixazomib (proteasome inhibitors, drugs that block the cell’s protein-recycling machinery): Ascorbate binds their boronic acid group and blocked bortezomib activity in cells and mice (Perrone 2009); possible loss of control of myeloma (a bone-marrow cancer). Common practice avoids infusions on dosing days.
  • Nephrotoxic (kidney-damaging) drugs (cisplatin, methotrexate, aminoglycoside antibiotics) and NSAIDs (nonsteroidal anti-inflammatory drugs such as ibuprofen, naproxen): Additive kidney stress alongside the oxalate load, inferred from shared kidney injury pathways. Hydration and a creatinine check before infusions lower this risk.
  • Oxidant drugs (rasburicase, dapsone, primaquine): Additive oxidative stress on red cells could trigger hemolysis in G6PD deficiency, inferred from shared oxidant mechanism. A normal G6PD test result removes this concern.
  • Antioxidant supplements (N-acetylcysteine, high-dose vitamin E, glutathione): May neutralize the hydrogen peroxide thought to drive tumor killing, inferred from redox chemistry; could blunt the intended effect. Common practice avoids them on infusion days.
  • Alpha-lipoic acid infusions (often co-infused in integrative clinics): In cells and mice it dampened ascorbate’s hydrogen peroxide, blunted tumor inhibition and increased toxicity (Chen 2024), inferred from thiol antioxidant chemistry; no human data. Common practice separates them.

Populations who should avoid High-Dose Vitamin C:

  • G6PD deficiency: The label limits doses to no more than the RDA (Recommended Dietary Allowance, 75–90 mg daily for adults) (ASCOR label); severe hemolysis is documented (Juneja 2022).
  • Kidney impairment or history of oxalate kidney stones: Listed as increased risk for oxalate nephropathy (ASCOR label); the label gives no specific kidney-function cutoff.
  • Pregnancy and lactation: The label limits doses to the RDA (ASCOR label).
  • Iron overload (transfusion-related overload in thalassemia, an inherited anemia; hereditary hemochromatosis, an inherited iron-storage disorder): Reversible cardiac dysfunction occurred with vitamin C above 500 mg daily during deferoxamine treatment (Desferal label); for hemochromatosis without deferoxamine, avoidance is inferred from iron mobilization; no human data.
  • Heart failure or required sodium restriction: Inferred from infusion volume and sodium content (each 25,000 mg vial is equivalent to 28,125 mg sodium ascorbate, ASCOR label); no human outcome data.

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • G6PD screening before the first infusion: Prevents hemolysis; with deficiency the label limits doses to the RDA (ASCOR label).
  • Kidney function check before starting and every 2–4 weeks: Reduces oxalate nephropathy risk, since a scoping review names prior kidney dysfunction a key risk factor (Carr 2026).
  • Hydration around infusions: Drinking 0.5–1 L of water before and after each infusion dilutes urinary oxalate and limits crystal formation and dehydration-related kidney injury.
  • Laboratory glucose instead of fingerstick for 24 hours: Prevents false hyperglycemia (high blood sugar) readings and wrong insulin dosing (Orija 2021, Rosengrave 2022).
  • Proper dilution and slow infusion: Undiluted ASCOR has an osmolarity (dissolved-particle concentration) near 5,900 mOsmol/L and must be diluted (ASCOR label); about 1 g/min was tolerated (Stephenson 2013). Reduces vein pain and phlebitis.
  • Stepwise dose escalation: Starting near 15–25 g and escalating over 2–3 infusions exposes intolerance, hemolysis or kidney stress before full doses are reached.
  • Keeping standard oncology treatment: Using infusions only alongside conventional therapy avoids the higher mortality seen when alternative medicine replaces it (Johnson 2018).
  • Stop on warning signs: Pausing infusions for dark urine, falling hemoglobin, reduced urine output or rising creatinine limits progression of hemolysis or oxalate kidney injury.

Therapeutic Protocol

Doses below are cited to their source; other parameters without a citation (e.g., timing, titration steps, infusion setting) reflect common practice.

  • Academic fixed-dose regimen (University of Iowa): 75 g three times weekly with gemcitabine and nab-paclitaxel (Bodeker 2024); 87.5 g three times weekly during radiation for glioblastoma, then twice weekly, targeting blood levels of at least 20 mM (Allen 2019).
  • Weight-based regimens: 1.5 g/kg three times weekly (Hoffer 2008); 1.5 g/kg daily on days 1–3 every 2 weeks with FOLFOX (Wang 2022); 1 g/kg with docetaxel (Paller 2024).
  • Integrative clinic practice (Riordan Clinic): Doses of 7.5–50 g after standard treatment (Mikirova 2012); its authors cite an average near 0.5 g/kg across complementary practitioners (Mikirova 2013); the clinic sells infusions.
  • Conventional versus integrative framing: Prostate trial investigators found no support for routine use outside trials in advanced prostate cancer resistant to hormone therapy (Paller 2024); oncologists from integrative and naturopathic cancer centers present infusions as supportive care (Klimant 2018).
  • Titration: Bladder cancer trial dosing starts at 25 g and is titrated to a target blood level (NCT06493370); common practice checks post-infusion vitamin C levels after escalation.
  • Infusion rate and duration: 1 g/min was tolerated (Stephenson 2013); a 75 g infusion takes about 2 hours (NCT02905591).
  • Time of day: No evidence favors a time of day; infusions are scheduled during clinic hours, often on chemotherapy days or overlapping radiation sessions (NCT02905591).
  • Half-life: About 2 hours; doses of 70–110 g/m² kept blood levels at or above 10–20 mM for 5–6 hours (Stephenson 2013).
  • Single versus split doses: Given as one infusion per session because peak concentration is the presumed driver; splitting lowers peaks, and oral doses cannot substitute (Padayatty 2004).
  • Genetic polymorphisms: G6PD deficiency limits doses to the RDA (ASCOR label); tumor RAS status may influence benefit (Wang 2022).
  • Sex differences: No sex-specific dosing exists; trials used the same weight-based or fixed doses for men and women.
  • Age: No age-specific regimen exists; older adults warrant closer kidney monitoring because the label lists geriatric patients as higher-risk (ASCOR label).
  • Baseline biomarkers: Low starting vitamin C, high CRP and metastatic burden lower achieved levels, so doses may need upward titration (Mikirova 2013).
  • Pre-existing conditions: Kidney impairment, iron overload, heart failure and insulin-treated diabetes call for lower doses, closer monitoring or avoidance (see Key Interactions & Contraindications).

Discontinuation & Cycling

  • Duration: Short-term and tied to a treatment course, not lifelong; the glioblastoma regimen continued through six chemotherapy cycles (Allen 2019), and the pancreatic regimen ran alongside chemotherapy (Bodeker 2024).
  • Withdrawal effects: No withdrawal syndrome has been reported after stopping intermittent infusions in clinical trials.
  • Tapering: No tapering protocol has been studied; some practitioners reduce frequency gradually after a treatment course, a common-practice choice rather than a requirement.
  • Cycling: Infusions are intermittent by design (two or three times weekly); cycling to maintain efficacy has not been studied.
  • Stopping triggers: Disease progression, rising creatinine, signs of hemolysis or completion of the companion chemotherapy course are the usual reasons to stop.

Sourcing and Quality

  • Approved injectable product: ASCOR (McGuff Pharmaceuticals) is the FDA-approved ascorbic acid injection, 500 mg/mL in 50 mL pharmacy bulk vials, labeled for scurvy only (ASCOR label); McGuff profits from its sales.
  • Compounded products: Other infusions come from compounding pharmacies; sterility, endotoxin (bacterial toxin) testing and accurate concentration matter, and buyers can request certificates of analysis.
  • Admixture preparation: The label requires preparation in a clean-air hood, use within 4 hours of vial puncture, light protection and no mixing with copper-containing solutions (ASCOR label).
  • Sodium ascorbate form: Injectable ascorbic acid is buffered to sodium ascorbate, which adds sodium (ASCOR label); in Europe, Pascorbin 7.5 g is a branded product from Pascoe (Vollbracht 2011).
  • Oral supplements are not equivalent: Oral vitamin C, including liposomal forms (vitamin C wrapped in tiny fat spheres), cannot reach the millimolar levels studied (Padayatty 2004); third-party oral product testing does not apply to infusion quality.

Practical Considerations

  • Time to effect: Survival effects in trials emerged over months (median survival 16.0 vs 8.3 months, Bodeker 2024); uncontrolled quality-of-life changes were reported within one week (Yeom 2007).
  • Time burden: Two or three clinic visits weekly, each with infusions of about 2 hours (NCT02905591), plus monitoring blood draws.
  • Common pitfalls: Relying on fingerstick glucose after infusion, assuming oral vitamin C is equivalent, skipping G6PD screening, under-dosing below target blood levels, and replacing proven treatment with infusions.
  • Regulatory status: Injectable ascorbic acid is approved only for scurvy (ASCOR label); the FDA has not approved high-dose vitamin C for cancer (National Cancer Institute PDQ summary). Cancer use is off-label.
  • Cost and access: A systematic review notes high financial and time costs for patients (Jacobs 2015); courses are usually paid out of pocket and are offered mainly by integrative clinics or within trials.
  • Structural funding bias: Ascorbate is unpatentable and cheap per gram, so no manufacturer funds large registration trials, and payers have little incentive to reimburse it; trial evidence depends on academic and public funding.

Interaction with Foundational Habits

  • Sleep: Indirect. Lethargy and fatigue were the most commonly reported infusion effects (Padayatty 2010), while a manufacturer-sponsored cohort reported fewer sleep disorders (Vollbracht 2011). Scheduling infusions earlier in the day avoids night-time urination from the fluid load.
  • Nutrition: Potentiating in mice: a fasting-mimicking diet (a cyclic plant-based, low-calorie, low-sugar diet) strengthened vitamin C’s effect against KRAS-mutant tumors (Di Tano 2020). Good hydration and moderating high-oxalate foods (spinach, rhubarb, nuts) around infusions limit oxalate load; iron-rich supplements deserve caution in iron overload.
  • Exercise: None documented. No study has measured how infusions interact with training; the infusion schedule competes with training time, and hydration supports both kidney safety and exercise tolerance.
  • Stress management: Indirect. Vitamin C is a cofactor in adrenal stress-hormone (noradrenaline) synthesis, but no study has measured cortisol or stress response during cancer infusions; reported improvements in depression and wellbeing come from uncontrolled or manufacturer-sponsored data (Vollbracht 2011).

Monitoring Protocol & Defining Success

Baseline testing before the first infusion establishes eligibility and safety: G6PD activity, kidney function, complete blood count, electrolytes, iron status and current tumor markers or imaging. For people with diabetes, laboratory glucose testing replaces fingerstick meters, which become unreliable after infusions.

Ongoing monitoring follows a set cadence: creatinine and electrolytes before each infusion during the first 2 weeks, then every 2–4 weeks; a post-infusion vitamin C level after each dose step until the target is reached; complete blood count every 2–4 weeks or immediately if urine darkens; and tumor markers or imaging every 2–3 months, in line with the oncology schedule. Success is defined by disease control and tolerance of standard treatment, not by blood vitamin C levels alone.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
G6PD activity Normal activity per laboratory (standard reference range) Safety check: deficiency stops or limits use Tested once before the first infusion; the label limits doses to the RDA with deficiency (ASCOR label)
Serum creatinine About 0.6–1.2 mg/dL (standard reference range) Safety check: rising values pause use A scoping review names prior kidney dysfunction a key risk factor for oxalate injury (Carr 2026); drawn before infusion, not only after
Peak plasma vitamin C At least 20 mM after infusion (Allen 2019 trial target) Marker the intervention is expected to change Target from Allen 2019; conventional fasting reference range is roughly 0.4–2.0 mg/dL (about 23–114 µM); drawn at the end of infusion
Hemoglobin and bilirubin Hemoglobin about 12–17.5 g/dL; total bilirubin about 0.1–1.2 mg/dL (standard reference range) Safety check: drops in hemoglobin or rising bilirubin signal hemolysis Usually paired with lactate dehydrogenase (LDH, a cell-damage enzyme); drawn before infusion
Serum sodium and potassium Sodium 135–145 mmol/L; potassium 3.5–5.0 mmol/L (standard reference range) Safety check: sodium load from sodium ascorbate Each 25,000 mg vial equals 28,125 mg sodium ascorbate (ASCOR label)
Ferritin and transferrin saturation Ferritin about 20–300 ng/mL; transferrin saturation about 20–50% (standard reference range) Safety check: iron overload stops or changes use Fasting morning sample preferred; tumor iron signal also predicted glioblastoma response (Petronek 2024)
Laboratory venous glucose Fasting 70–99 mg/dL (standard reference range) Safety check: replaces unreliable meters Fingerstick results are unreliable during and up to 24 hours after infusion (ASCOR label)
Tumor markers and imaging No established target; track change from the individual’s own baseline Marker the intervention is expected to change The marker depends on the cancer type (e.g., CA 19-9, a pancreatic tumor marker); imaging is compared with pre-treatment scans

Qualitative markers:

  • Energy level and fatigue across the week after infusions
  • Appetite, nausea and tolerance of chemotherapy cycles
  • Pain levels and need for pain medication
  • Infusion-site comfort, thirst and urine color
  • Ability to keep up daily activities and exercise

Emerging Research

  • Glioblastoma phase 2 (NCT02344355): 90 participants, 87.5 g with radiation and temozolomide, overall survival primary; published results from 55 participants exceeded historical controls (Petronek 2024). Positive: strengthens the brain-tumor case; null: confines interest to other cancers.
  • Bladder cancer phase 2 (NCT06493370): 48 participants, ascorbate with gemcitabine–carboplatin, pathological staging after treatment primary. Positive: adds a new tumor type with a hard tissue endpoint; null: weakens the general chemotherapy-partner rationale.
  • Lymphoma and blood precancers phase 2 (NCT03418038): 80 participants with lymphoma, clonal cytopenia or chronic myelomonocytic leukemia (a blood cancer), response rate primary; the clonal cytopenia arm showed no responses (Xie 2024). Positive: supports the TET2 rationale; null: weakens it further.
  • Acute myeloid leukemia (an aggressive blood cancer) phase 1 (NCT07177079): 30 participants, ascorbate with azacitidine and venetoclax, dose-limiting toxicity and remission primary. Positive: opens a leukemia combination; null: limits use to solid tumors.
  • KRAS-mutant colorectal cancer phase 1b (NCT06336902): 15 participants, vitamin C with fasting-mimicking diet and immunotherapy, safety and adherence primary. Positive: supports diet and immune combinations; null: tempers mouse-based enthusiasm.
  • Colorectal phase 3 with adebrelimab (NCT04516681): 400 participants, response rate primary; the registered completion date (December 2025) has passed, the record was last updated October 2024, and no results are posted.
  • KRAS-targeted patient selection: Mouse data (Yun 2015), the colorectal RAS subgroup (Wang 2022) and a responding duodenal case (Mack 2025) suggest RAS-selected trials could sharpen or refute the survival signal.
  • Immunotherapy combinations: Curative effects with checkpoint inhibitors in mice (Magrì 2020) and rising CD8 T cells (cancer-killing immune cells) in a lung trial (Furqan 2022) await controlled human testing.
  • Resistance and metastasis concern: Resistant pancreatic cancer cells became more metastatic in mice (Pope 2025), a finding that could weaken the case if confirmed in patients.
  • Iron-based biomarkers: Imaging of tumor iron predicted glioblastoma response (Petronek 2024), offering a way to select likely responders in future trials.

Conclusion

High-dose vitamin C means repeated infusions that push blood levels of the vitamin far beyond what food or oral supplements can reach, with the aim of stressing cancer cells while sparing normal tissue. For proactive patients considering it as an add-on to cancer treatment, the evidence is mixed rather than settled in either direction.

The strongest support concerns survival. Pooled studies and a small pancreatic cancer trial point toward longer life when infusions accompany chemotherapy, and an early brain tumor trial looked encouraging. Yet the largest trial, in bowel cancer, showed no overall gain, and a prostate cancer trial stopped early with a trend in the wrong direction that may have been chance. Claims of fewer chemotherapy side effects and better quality of life rest mostly on reports without comparison groups or on company-funded reports and were not confirmed when compared with placebo.

Infusions are generally well tolerated when people are screened. The documented harms are uncommon but serious: kidney damage from crystals that form as the vitamin breaks down, mostly in people with reduced kidney function; destruction of red blood cells in people with an inherited enzyme shortage; and misleading fingerstick sugar readings. Abandoning proven treatment in favor of infusions carries the greatest risk.

The evidence base is small, spread across many cancer types, and often without comparison groups. Much supportive literature comes from clinics or companies that sell infusions, while the vitamin’s lack of patent protection limits industry funding for large trials. Results may differ by tumor type.

Top - Benefits - Risks - Protocol